Melissa Rhodes, PhD, DABT

Chief Development Officer

Melissa Rhodes is the Chief Development Officer of Kriya Therapeutics. Previously, Dr. Rhodes was the Chief Development Officer of Aerami Therapeutics, a company focused on inhaled biologic therapies. Prior to Aerami, Dr. Rhodes was the Chief Development Officer of Altavant Sciences, a respiratory rare disease company. Dr. Rhodes also served as Senior Vice President at Roivant Sciences, where she built and led a team of scientists conducting nonclinical research for multiple Roivant subsidiary companies. She spent nearly ten years in R&D at GlaxoSmithKline, and started her career in drug development at an oncology-focused university spin-out company.

Dr. Rhodes received her PhD in Pharmacology and Toxicology from Duke University Medical Center and is a Diplomate of the American Board of Toxicology. Dr. Rhodes completed her postdoctoral fellowship at the National Toxicology Program at the National Institute of Environmental Health Sciences. She received her undergraduate degree in Zoology from North Carolina State University.